


10/518652

DT01 Rec'd PCT/PTO 16 DEC 2004

In the Claims:

1. (original) Compound of formula (I):



in which


X represents N or CH;

R₁ represents a hydrogen or halogen atom or a CF₃ group;

R₂ and R₃ independently represent a hydrogen atom or a methyl group;

n is 0 or 1;

W represents a diazoheterocycle of formula (a) to (d)




(a)



(b)




(c)




(d)

A represents a group of formula (e) or (f)



(e)



(f)

where

R₄ represents a hydrogen or halogen atom, a (C₁-C₄)alkyl group, a CF₃ group, an amino, a mono(C₁-C₄)alkylamino or a di(C₁-C₄)alkylamino group;

R₅ represents a hydrogen or halogen atom, a (C₁-C₄)alkoxy group, a (C₁-C₄)alkyl group or a CF₃ group;

R₆ represents a hydrogen atom, a (C₁-C₄)alkyl group or a (C₁-C₄)alkoxy group; it being possible for only one or both of the atoms of the rings (a) to (d) to be oxidized;

and their salts or solvates.

2. **(original)** Compound according to Claim 1, where n is zero.

3. **(currently amended)** Compound according to Claim 1 ~~or 2, where wherein~~ R₂ and R₃ are each a hydrogen atom.

4. **(currently amended)** Compound according to Claim 1 ~~or 2, where wherein~~ R₁ is a CF₃ group.

5. **(currently amended)** Compound according to Claim 1 ~~or 2, where wherein~~ R₁ is a fluorine or chlorine atom.


6. **(currently amended)** Compound according to ~~Claims 1 to 3, where Claim 1 wherein~~ X is CH and R₁ is at the 3-position of the benzene.

7. **(currently amended)** Compound according to ~~Claims 1 to 3, where Claim 1 wherein~~ X is CH and R₁ is at the 2-position of the benzene.


8. **(currently amended)** Compound according to ~~Claims 1 to 3, where Claim 1 wherein~~ X is N and the pyridine is substituted at the 2,6-positions.

9. **(currently amended)** Compound according to ~~Claims 1 to 8, Claim 1~~ chosen from its mono-N-oxide derivatives, its bis-N-oxides and its tri-N-oxides.

10. (currently amended) Method A method for preparing the compound of Claim 1, characterized in that wherein there are carried out a condensation/reduction reaction of a compound of formula (II):




in which X, W and R₁ are as defined in Claim 1, with an aldehyde of formula (III):



in which R₂, R₃, n and A are as defined above, the isolation of the compound of formula (I) and the optional conversion to one of its salts or solvates or to its N-oxide derivatives.

11. (original) Compound of formula (II')



in which W represents a group of formula (b) or (c) according to Claim 1, and its salts or solvates.

12. (currently amended) Pharmaceutical A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to ~~Claims 1 to 9~~ Claim 1 or one of its pharmaceutically acceptable salts or solvates.

13. (currently amended) Composition according to Claim 12, characterized in that wherein it contains from 0.001 to 100 mg of active ingredient.

14. (currently amended) ~~Use of a compound of formula (I) according to Claims 1 to 9 or of one of its pharmaceutically acceptable salts or solvates for the preparation of analgesic medicaments and/or intended A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 1.~~

15. (cancelled)

16. (new) Compound according to Claim 2 wherein R₂ and R₃ are each a hydrogen atom.

17. (new) Compound according to Claim 2 wherein R₁ is a CF₃ group.

18. (new) Compound according to Claim 2 wherein R₁ is a fluorine or chlorine atom.

19. (new) Compound according to Claim 2 wherein X is CH and R₁ is at the 3-position of the benzene.

20. (new) Compound according to Claim 3 wherein X is CH and R₁ is at the 3-position of the benzene.

21. (new) Compound according to Claim 2 wherein X is CH and R₁ is at the 2-position of the benzene.

22. (new) Compound according to Claim 3 wherein X is CH and R₁ is at the 2-position of the benzene.

23. (new) Compound according to Claim 2 wherein X is N and the pyridine is substituted at the 2,6-positions.

24. (new) Compound according to Claim 3 wherein X is N and the pyridine is substituted at the 2,6-positions.

25. (new) A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 2 or one of its pharmaceutically acceptable salts or solvates.
26. (new) A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 3 or one of its pharmaceutically acceptable salts or solvates.
27. (new) A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 4 or one of its pharmaceutically acceptable salts or solvates.
28. (new) A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 5 or one of its pharmaceutically acceptable salts or solvates.
29. (new) A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 6 or one of its pharmaceutically acceptable salts or solvates.
30. (new) A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 7 or one of its pharmaceutically acceptable salts or solvates.
31. (new) A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 8 or one of its pharmaceutically acceptable salts or solvates.
32. (new) A pharmaceutical composition containing, as active ingredient, a compound of formula (I) according to Claim 9 or one of its pharmaceutically acceptable salts or solvates.
33. (new) A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 2.
34. (new) A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 3.
35. (new) A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 4.

36. (new) A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 5.

37. (new) A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 6.

38. (new) A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 7.

39. (new) A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 8.

40. (new) A method for the treatment of diseases linked to immune and inflammatory disorders or for the treatment of pain which comprises administering to a patient in need thereof an effective amount of a compound according to claim 9.